Home > Healthcare > Medical Devices > Diagnostic Devices > Blood Culture Tests Market

Blood Culture Tests Market Trends

Report ID: GMI7701
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Blood Culture Tests Market Trends

Blood culture tests play a pivotal role in the diagnosis and management of bloodstream infections, providing critical insights for effective medical intervention. As healthcare continues to evolve, several trends are shaping the increasing demand for sepsis diagnostics, reflecting a growing recognition of their significance in infectious disease diagnostics and patient care.

As per estimates from the World Health Organization (WHO), out of every 100 patients admitted under acute care in hospitals, 15 patients in low-and-middle-income countries and 7 patients in high-income countries will be infected by any one of the hospital-acquired infections during their hospital stay.
Moreover, rapid, and reliable diagnostic tools not only enable healthcare professionals to identify infection early in its course but also facilitates targeted and timely treatment strategies.
Governments around the globe are increasingly acknowledging the profound impact of infectious diseases on public health, prompting a surge in initiatives aimed at mitigating their effects. For instance, in November 2022, the U.S. Centers for Disease Control and Prevention (CDC) initiated a USD 3.2 billion grant program to fortify the nationwide public health infrastructure.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of blood culture tests was worth USD 5.8 billion in 2022 and is estimated to reach USD 11.5 billion by 2032 as these tests are crucial in identifying and diagnosing bloodstream infections, which can be serious and life-threatening if not promptly treated.

The consumables segment garnered USD 3.5 billion in 2023 and will grow significantly through 2032, due to an increased emphasis on the quality of culture media.

U.S. blood culture tests market accounted for USD 2.2 billion in 2023 and is predicted to witness substantial growth through 2032, owing to the increasing healthcare investments, a rising burden of infectious and chronic diseases, and efforts to expand healthcare access.

Becton, Dickinson and Company, Terumo Corporation, bioMerieux SA, Bruker Corporation, T2 Biosystems Inc., Abbott Laboratories, Luminex Corporation, Siemens Healthineers AG, F. Hoffmann-La Roche AG, Danaher Corporation, Neogen Corporation, and Thermo Fisher Scientific Inc.